Triptolide (TP) is the major bioactive compound extracted from Tripterygium wilfordii Hook F. It exerts anti-inflammatory, antirheumatic, antineoplastic, and neuroprotective effects. However, the severe hepatotoxicity induced by TP limits its clinical application. Ginsenoside Rb1 has been reported to possess potential hepatoprotective effects, but its mechanism has not been fully investigated. This study was aimed at investigating the effect of ginsenoside Rb1 against TP-induced cytotoxicity in HL-7702 cells, as well as the underlying mechanism. The results revealed that ginsenoside Rb1 effectively reversed TP-induced cytotoxicity in HL-7702 cells. Apoptosis induced by TP was suppressed by ginsenoside Rb1 via inhibition of death receptor-mediated apoptotic pathway and mitochondrial-dependent apoptotic pathway. Pretreatment with ginsenoside Rb1 significantly reduced Bax/Bcl-2 ratio and down-regulated the expression of Fas, cleaved poly ADP-ribose polymerase (PARP), cleaved caspase-3, and -9. Furthermore, ginsenoside Rb1 reversed TP-induced cell cycle arrest in HL-7702 cells at S and G2/M phase, via upregulation of the expressions of cyclin-dependent kinase 2 (CDK2), cyclin E, cyclin A, and downregulation of the expressions of p53, p21, and p-p53. Ginsenoside Rb1 increased glutathione (GSH) and superoxide dismutase (SOD) levels, but decreased the reactive oxygen species (ROS) and malondialdehyde (MDA) levels. Pretreatment with ginsenoside Rb1 enhanced the expression levels of nuclear factor-erythroid 2-related factor 2 (Nrf2), total Nrf2, NAD(P)H: quinone oxidoreductases-1 (NQO-1), heme oxygenase-1 (HO-1), and Kelch-like ECH-associated protein 1 (Keap1)/Nrf2 complex. Therefore, ginsenoside Rb1 effectively alleviates TP-induced cytotoxicity in HL-7702 cells through activation of the Keap1/Nrf2/ARE antioxidant pathway.
The introduction of different pore diameters in metal
organic frameworks
(MOFs) could adjust their drug delivery performance. MOFs with customized
structures have potential application value in targeted drug delivery.
However, no research on this topic has been found so far. In this
report, isoreticular metal organic frameworks (IRMOFs) have been taken
as a typical case of tailor-made MOFs, the pore size of which is enlarged
(average BJH pore sizes of about 2.43, 3.06, 5.47, and 6.50 nm were
determined for IRMOF-1, IRMOF-8, IRMOF-10, and IRMOF-16, respectively),
emphasizing the relationship between pore size and model drugs (Oridonin,
ORI) and clarifying its potential working mechanism. IRMOF-1, whose
pore size matches the size of ORI, has an outstanding drug loading
capacity (57.93% by wt) and release profile (about 90% in 24 h at
pH 7.4). IRMOF-1 was further coated with polyethylene glycol (PEG)
modified with a cell penetrating peptide (CPP44) bound to M160 (CD163L1)
protein for targeting of hepatic tumor lines. This nanoplatform (CPP44-PEG@ORI@IRMOF-1)
exhibited acid-responsive drug release behavior (37.86% in 10 h at
pH 7.4 and 66.66% in 10 h at pH 5.5) and significantly enhanced antitumor
effects. The results of cell targeting and in vivo animal imaging
indicated that CPP44-PEG@ORI@IRMOF-1 may serve as a tumor-selective
drug delivery nanoplatform. Toxicity assessment confirmed that PEGylated
IRMOF-1 did not cause organ or systemic toxicity. Furthermore, it
is encouraging that the IRMOF-based targeted drug delivery system
with pore size modulation showed rapid clearance (most administered
NPs are metabolized from urine and feces within 1 week) and avoided
accumulation in the body, indicating their promise for biomedical
applications. This MOF-based aperture modulation combined with a targeted
modification strategy might find broad applications in cancer theranostics.
Thus, it is convenient to customize personalized MOFs according to
the size of drug molecules in future research.
Photodynamic therapy (PDT) and photothermal therapy (PTT) have attracted research interest for their noninvasive nature and selective treatment of tumor tissues. They are effective through the generation of reactive oxygen species (ROS) or heat. Nevertheless, several problems, including low bioavailability and long-lasting cutaneous photosensitivity, have limited their clinical application. In this study, we reported an in situ self-assembly strategy that could improve various biological properties of the photosensitizer
in vivo
. A photosensitizer connected to a receptor-mediated smart peptide can self-assemble into nanoparticles (NPs) under the force of hydrophobic interaction and then transform into a nanofibrillar network after attaching to the tumor cell surface with the help of the β-sheet-forming peptide KLVFF. The supramolecular structural changes deeply affected the PDT and PTT properties of the photosensitizer on tumors. After being aggregated into the nanostructure, the water solubility and targeting ability of the photosensitizer was ameliorated. Moreover, the improvement of the photothermal conversion efficiency, ROS generation, and tumor retention followed the formation of nanofibrils (NFs). This self-assembly strategy showed the ability of supramolecular nanofibrils to improve the bioavailability of photosensitizers, which provides a new potential treatment avenue for various cancer therapies.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.